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Abstract RNA-binding protein pathology now represents
one of the best characterized pathologic features of
amyotrophic lateral sclerosis (ALS) and frontotemporal
lobar degeneration patients with TDP-43 or FUS pathology
(FTLD-TDP and FTLD-FUS). Using liquid chromatogra-
phy tandem mass spectrometry, we identified altered levels
of the RNA-binding motif 45 (RBM45) protein in the
cerebrospinal fluid (CSF) of ALS patients. This protein
contains sequence similarities to TAR DNA-binding pro-
tein 43 (TDP-43) and fused-in-sarcoma (FUS) that are
contained in cytoplasmic inclusions of ALS and FTLD-
TDP or FTLD-FUS patients. To further characterize
RBM45, we first verified the presence of RBM45 in CSF
and spinal cord tissue extracts of ALS patients by immu-
noblot. We next used immunohistochemistry to examine
the subcellular distribution of RBM45 and observed in a
punctate staining pattern within nuclei of neurons and glia
in the brain and spinal cord. We also detected RBM45
cytoplasmic inclusions in 91 % of ALS, 100 % of FTLD-
TDP and 75 % of Alzheimer’s disease (AD) cases. The
most extensive RBM45 pathology was observed in patients
that harbor the C9ORF72 hexanucleotide repeat expansion.
These RBM45 inclusions were observed in spinal cord
motor neurons, glia and neurons of the dentate gyrus. By
confocal microscopy, RBM45 co-localizes with ubiquitin
and TDP-43 in inclusion bodies. In neurons containing
RBM45 cytoplasmic inclusions we often detected the
protein in a punctate pattern within the nucleus that lacked
either TDP-43 or ubiquitin. We identified RBM45 using a
proteomic screen of CSF from ALS and control subjects
for candidate biomarkers, and link this RNA-binding pro-
tein to inclusion pathology in ALS, FTLD-TDP and AD.
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Introduction
Amyotrophic lateral sclerosis (ALS) is the most frequent
adult-onset motor neuron disease and is characterized by a
degeneration of motor neurons, leading to progressive muscle
weakening and a typical life expectancy of 2–5 years after
disease onset [4]. Frontotemporal lobar degeneration (FTLD)
is the second most frequent cause of dementia and is a clini-
cally diverse syndrome, with phenotypes including behavioral
changes, semantic dementia and progressive non-fluent
aphasia, and characterized by cellular inclusions containing
tau (FTLD-tau), TAR DNA-binding protein 43 (TDP-43:
FTLD-TDP) or fused-in-sarcoma (FUS: FTLD-FUS) [25, 28].
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The presence of cytoplasmic inclusions positive for
ubiquitin in degenerating neurons is a pathological hall-
mark of ALS and FTLD [15, 19]. The observation that
some ALS patients develop cognitive deficits with promi-
nent frontal lobe features, and that the associated
neuropathology resembles that of FTLD led to the idea that
ALS and FTLD might be related [21, 33]. An intronic
hexanucleotide repeat expansion in the C9ORF72 gene
(GGGGCC) has recently been shown to be the genetic
cause of chromosome 9p21-linked ALS-FTLD, and
accounts for 30–40 % of familial ALS and a similar por-
tion of familial FTLD, further linking these two
neurodegenerative disorders [8, 38]. RNA generated from
genomic non-coding repeat expansions may disrupt normal
RNA metabolism by sequestering RNAs and proteins
involved in other transcription/translation events [46].
TDP-43 and FUS have been identified as components of
ubiquitinated inclusions occurring in ALS patients without
Cu/Zn superoxide dismutase mutations and in FTLD
patients [23, 25]. Both TDP-43 and FUS are primarily
located in the nucleus of cells, but mislocalize and form
neuronal and glial inclusions in ALS, FTLD-TDP and
FTLD-FUS [3, 17, 35]. Mutations in TDP-43 and FUS
have been identified as a genetic cause in approximately
4 % of familial ALS and in rare cases of FTLD [27]. Both
TDP-43 and FUS bind numerous RNAs (reviewed in [17,
42]) and are abnormally processed in ALS [47], linking
altered RNA metabolism to ALS, FTLD-TDP and FTLD-
FUS [42].
During an unbiased mass spectrometry-based proteomic
analysis of cerebrospinal fluid (CSF) from ALS and control
subjects, we detected an increase in the RNA-binding motif
45 (RBM45) protein in the CSF of ALS patients. This
protein is expressed at highest levels in the brain [44], and
has been suggested to be up-regulated in animal models of
spinal cord injury and nerve degeneration [32]. Further-
more, RNA recognition motifs are conserved between
RBM45, TDP-43 and FUS. Therefore, we sought to further
characterize RBM45 expression and distribution in the
brain and spinal cord of ALS, FTLD-TDP and control
subjects.
RBM45 protein was detected in the CSF and central
nervous tissue of ALS and control subjects. We observed
RBM45 in a punctate pattern predominately in the nucleus
of neurons and glia in the hippocampus and spinal cord of
control subjects. In ALS patients, RBM45 was also con-
tained in cytoplasmic inclusions in motor neurons that were
immunoreactive for TDP-43 and ubiquitin. RBM45 was
evident within cytoplasmic inclusions in 100 % of FTLD-
TDP and 75 % of AD patients. In contrast to TDP-43, we
also detected RBM45 in the nucleus of neurons containing
cytoplasmic inclusions. Finally, the most abundant RBM45
pathology was observed in ALS patients that harbor the
hexanucleotide repeat expansion of the C9ORF72 gene.
Thus, RBM45 represents a new RNA-binding protein




ALS and control post-mortem fixed and frozen tissue was
obtained from the University of Pittsburgh Brain Bank and
the Center for ALS Research. Clinical diagnoses were
made by board certified neuropathologists according to
consensus criteria for each disease. All human tissues were
obtained through a process that included written informed
consent by the subjects’ next of kin. The acquisition pro-
cess was evaluated by the University of Pittsburgh
Institutional Review Board/University of Pittsburgh Com-
mittee for Oversight of Research Involving the Dead and
determined to be exempt from review by the full com-
mittee. Subject demographics are listed in Table 1. The
average age for each subject category was 59.7 ± 11.2
years for ALS, 60.2 ± 11.2 years for controls, 76.7 ±
9.9 years for frontotemporal lobar degeneration with
TDP-43 inclusions (FTLD-TDP) and 78.2 ± 7.3 years for
Alzheimer’s disease (AD) patients. The post-mortem
interval for each subject group was 7.3 ± 4.6 h for ALS,
6.6 ± 5.0 h for controls, 9.0 ± 7.5 h for FTLD-TDP, and
4.5 ± 1.0 h for AD patients. While there was a statistically
significant difference in age across the subject groups due
to the more advanced age of the FTLD-TDP and AD cases
(p = 0.01), there was no significant difference of post-
mortem interval (p = 0.6). All FTLD-TDP cases either
presented with motor neuron disease or developed motor
neuron deficits and were best fit neuropathologic criteria
for FTLD-TDP type B with TDP-43 inclusions in spinal
cord motor neurons and frontal and/or temporal cortex
[24]. All AD cases were Braak stage VI with frequent
plaque pathology by CERAD criteria [30, 31]. Two of four
AD cases had additional TDP-43 pathology in the hippo-
campus, as noted in Table 2.
CSF collection, processing and mass spectrometry-
based proteomics
The study population comprised 90 sporadic ALS (SALS),
20 familial ALS (fALS), 20 multiple sclerosis (MS), 20
Alzheimer’s disease (AD), 10 lower motor neuron disease
(LMND), 5 upper motor neuron disease (UMND) and 80
healthy control (HC) subjects. Revised El Escorial criteria
were used to diagnose all ALS subjects [5], with 18 %
diagnosed as definite ALS, 33 % probable ALS, 24 %
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probable/lab supported ALS and 25 % possible ALS.
Healthy controls were typically spouses or family friends
of the ALS patients. Of the FALS patients, three had SOD1
mutations. All LMND subjects exhibited only lower motor
neuron symptoms at the time of the lumbar spinal tap. All
UMND subjects exhibited only upper motor neuron
symptoms at the time of the lumbar spinal tap. CSF sam-
ples (between 3 and 10 mL per subject) were obtained by
lumbar puncture from subjects upon informed patient
consent. All samples were spun at 3,000 rpm at 4 C for
10 min to remove any cells and debris, aliquoted in small
volumes and stored in low bind polypropylene tubes at
-80 C within 2 h from harvesting. Only CSF samples
without visible blood were processed by centrifugation,
and hemoglobin levels in all final CSF samples were
measured by ELISA to eliminate those with evidence of
significant levels of hemoglobin denoting blood
contamination.
We generated 25 pooled samples (Table 3), each con-
taining 200 ll of CSF from 10 subjects that were age and
gender-matched. CSF samples were concentrated using
Amicon Ultra 3 K columns (Millipore) and adjusted to a
volume of 400 ll using a 49 solution of Agilent Buffer A.
Abundant proteins were depleted using the Agilent Multi-
Affinity Removal spin cartridge that removes six highly
abundant proteins according to the manufacturer’s proto-
col. Depleted samples were buffer exchanged into 50-mM
ammonium bicarbonate (NH4HCO3) by centrifugation
using AmiconUltra 3 K columns to a final volume of
300 ll and protein concentrations were determined by
BCA (Pierce).
The samples were reduced with addition of 10-mM DTT
at 56 C for 30 min, alkylated in 55 mM iodoaceteamide in
the dark for 30 min, and 3 ll of 1 % ProteasMAX (Pro-
mega) and Trypsin Gold (Promega) were added at a 1:20
ratio and digested at 37 C for 9 h. Finally, 15.75 ll of 1 %
TFA was added and the samples stored at -80 C. All
samples were then de-salted using PIERCE Pepclean C-18
spin columns, peptides eluted with 0.1 % TFA and 60 %
ACN and dried by vacuum centrifugation.
Peptide digests were resuspended in 0.1 % TFA and
analyzed in triplicate by nanoflow reversed-phase liquid
chromatography (LC)-MS/MS using a Dionex Ultimate
3000 LC system (Dionex Corporation, Sunnyvale, CA)
coupled online to a linear ion trap (LIT) mass spectrometer
(LTQ, ThermoFisher Scientific, San Jose, CA). Separations
were performed using 75-lm i.d. 9 360 o.d. 9 10 cm
long fused silica capillary columns (Polymicro Technolo-
gies, Phoenix, AZ) that were slurry packed in house with
5 lm, 300 A˚ pore size C-18 silica-bonded stationary phase
(Jupiter, Phenomenex, Torrance, CA). Following sample
Table 1 Subject demographics
Case ID Group Age Gender PMT C9ORF72 repeat
expansion
1 ALS 40 M 6 No
2 ALS 68 M 4 Yes
3 ALS 43 M 6 Yes
4 ALS 45 M 7 No
5 ALS 62 M 7 No
6 ALS 72 F 9 No
7 ALS 69 M 5 No
8 ALS 50 F 7 No
9 ALS 60 F 4 No
10 ALS 59 M 4 No
11 ALS 77 F 4 No
12 ALS 79 F 4 No
13 ALS 52 F 21 No
14 ALS 45 M 7 No
15 ALS 65 M 5 No
16 ALS 66 M 18 No
17 ALS 53 F 12 No
18 ALS 73 F 6 No
19 ALS 59 M 5 No
20 ALS 70 F 4.5 No
21 FALS 55 M 14 No
22 FALS 63 F 4 Yes
23 FALS 48 F 5 No
24 FTLD-TDP 69 M 6 No
25 FTLD-TDP 67 M 24 No
26 FTLD-TDP 69 M 6 No
27 FTLD-TDP 85 M 3 No
28 FTLD-TDP 91 F 8 No
29 FTLD-TDP 79 M 7 No
30 AD 73 F 4 No
31 AD 71 M 4 No
32 AD 85 M 5 No
33 AD 84 F 5 No
34 CT 54 M 6 No
35 CT 53 F 4 No
36 CT 76 M 13 No
37 CT 57 M 2 No
38 CT 48 M 2 No
39 CT 58 F 5 No
40 CT 76 M 14 No
Subject case number, disease group, age, gender, PMT (post-mortem
interval), and the presence or absence of the C9ORF72 repeat
expansion. All AD cases were Braak stage VI
ALS amyotrophic lateral sclerosis, FALS familial amyotrophic lateral
sclerosis, FTLD-TDP frontotemporal lobar degeneration with TDP-43




Table 2 Immunohistochemistry results for RBM45 and TDP-43
Case ID Lumbar spinal cord Hippocampus
RBM45 pathology TDP-43 pathology RBM45 pathology TDP-43 pathology
NCI GCI NCI GCI NCI GCI NCI GCI
1 ?? ?? ?? ?? NA NA NA NA
2* ??? ?? ??? ? NA NA NA NA
3* ??? ?? ??? ? NA NA NA NA
4 ?? ?? ? ? NA NA NA NA
5 ? ? ? ? NA NA NA NA
6 ? ?? ?? ??? NA NA NA NA
7 - - ? ?? ? - ? -
8 - ? ? ? NA NA NA NA
9 ?? - ?? ??? NA NA NA NA
10 ?? ? ?? ?? ? - ? -
11 ?? ? ? ? NA NA NA NA
12 ? ??? ? ?? - - ? -
13 ? ? ? - ?? - ? -
14 ?? ?? ? ? ? - ?? -
15 ?? ?? ? ?? - - - -
16 - - ?? ? - - ? -
17 ? ? ? - ??? - ?? -
18 - - ? ? NA NA NA NA
19 ? - ? ? NA NA NA NA
20 ?? ?? ?? ?? NA NA NA NA
21 - ? ? - NA NA NA NA
22* ?? ? ?? ? - - ? -
23 ? ? ?? ??? NA NA NA NA
24 ? ? ? ? ?? - ?? -
25 ? - ? ? - - ??? -
26 NA NA NA NA ? - ??? -
27 NA NA NA NA ??? - ??? -
28 NA NA NA NA ??? - ??? -
29 NA NA NA NA ? - ?? -
30 NA NA NA NA ??? - ??? -
31 NA NA NA NA ?? - ?? -
32 NA NA NA NA - - - -
33 NA NA NA NA ?? - ? -
34 - - - - - - - -
35 - - - - - - - -
36 - - - - NA NA NA NA
37 - - - - NA NA NA NA
38 - - - - - - - -
39 - - - - - - - -
40 - - - - - - - -
Cytoplasmic inclusions were counted in at least three tissue sections from each region
(-), no inclusions; (?), 1–3 inclusions per section; (??), 4–9 inclusions per section; (???), greater than 10 inclusions per section
NCI neuronal cytoplasmic inclusions, GCI glial cytoplasmic inclusions
* Denotes cases with C9ORF72 repeat expansion
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injection onto a C-18 trap column (Dionex), the column
was washed for 3 min with mobile phase A (2 % ace-
tonitrile, 0.1 % formic acid in water) at a flow rate of
30 ll/min. Peptides were eluted using a linear gradient of
0.3 % mobile phase B (0.1 % formic acid in acetoni-
trile)/min for 130 min, then to 95 % B in an additional
10 min, all at a constant flow rate of 0.20 ll/min. Col-
umn washing was performed at 95 % B for 20 min, after
which the column was re-equilibrated in mobile phase A
prior to subsequent injections. The LIT-MS was operated
in a data-dependent MS/MS mode in which each full MS
scan was followed by five MS/MS scans where the five
most abundant peptide molecular ions are selected for
collision-induced dissociation (CID), using a normalized
collision energy of 30 %. Data were collected over a
broad mass to charge (m/z) precursor ion selection scan
range of 375–1,800, utilizing dynamic exclusion to
minimize redundant selection of peptides previously
selected for CID.
Tandem mass spectra were searched against a combined
UniProt human protein database (7/09 release) from the
European Bioinformatics Institute (http://www.ebi.ac.uk/
integr8) using SEQUEST (ThermoFisher Scientific). For a
fully tryptic peptide to be considered legitimately identi-
fied, it had to achieve stringent charge state and proteolytic
cleavage-dependent cross-correlation (9corr) scores of 1.9
for [M ? H]1?, 2.2 for [M ? 2H]2? and 3.5 for
[M ? 3H]3?, and a minimum delta correlation (DCn) of
0.08. In addition, peptides were searched for methionine
oxidation with a mass addition of 15.9949 and serine,
threonine and tyrosine phosphorylation with a mass addi-
tion of 79.9663. A false peptide discovery rate less than
2 % was determined by searching the primary tandem MS
data using the same criteria against a decoy database
wherein the protein sequences are reversed [10]. Results
were further filtered using software developed in-house,
and differences in protein abundance between the samples
were derived by summing the total CID events that resulted
in a positively identified peptide for a given protein
accession across all samples (spectral counting) [20]. Sta-
tistical analysis across the sample groups using the number
of peptides for each protein was performed by unpaired
t test using GraphPad Prism 5.0 software (La Jolla, CA).
Effect size of each protein was determined using the
number of peptides for each group and comparing all ALS
groups versus all other groups, using the equation:
Effect size
¼ Mean of all ALS groups½   Mean of all other groups½ 
standard deviation
where standard deviation represents the standard deviation
of all non-ALS groups [13].
Immunohistochemistry
Paraffin-embedded tissue sections of spinal cord from ALS
(n = 23), FTLD-TDP (n = 2), and non-neurologic disease
control (n = 7), and hippocampus from ALS (n = 9),
FTLD-TDP (n = 6), Alzheimer’s disease (n = 4) and non-
neurologic disease control (n = 5) cases were used for this
study. All sections were deparaffinized, rehydrated and
antigen retrieval performed using Target Antigen Retrieval
Solution, pH 9.0 (DAKO) for 20 min in a steamer. After
cooling to room temperature, non-specific binding sites
were blocked using Super Block (Scytek) for 1 h. The
following primary antibodies were used for immunohisto-
chemistry: affinity-purified rabbit polyclonal anti-RBM45
generated to amino acids 1–130 (1:75; Sigma-Aldrich
Prestige antibody HPA020448), custom-made affinity-
purified rabbit monoclonal antibody to the C-terminal 15
amino acids of RBM45 (1:200 dilution; PI462476),
Table 3 Subject groups used for mass spectrometry based
proteomics
Group # Subject type Age (years)
1 SALS, limb onset \40
2 SALS, limb onset \40
3 SALS, limb onset 40–60
4 SALS, limb onset, taking riluzole 40–60
5 SALS, limb onset, taking riluzole 40–60
6 SALS, bulbar onset 40–60
7 SALS, limb onset [60
8 SALS, limb onset, taking riluzole [60
9 SALS, bulbar onset [60
10 FALS 40–60
11 FALS [60
12 Healthy controls \40
13 Healthy controls \40
14 Healthy controls \40
15 Healthy controls 40–60
16 Healthy controls 40–60
17 Healthy controls 40–60
18 Healthy controls [60
19 Healthy controls [60
20 Multiple sclerosis \40
21 Multiple sclerosis 40–70
22 Lower motor neuron disease (LMN)
23 Upper motor neuron disease (UMN)
24 Alzheimer’s disease [60
25 Alzheimer’s disease [60
Each group contains 100 ll of CSF from each of 10 individuals,
comprising six males and four females
SALS sporadic ALS, FALS familial ALS
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affinity-purified rabbit polyclonal anti-RBM45 antibody
AV41154 (Sigma-Aldrich), rabbit polyclonal anti-TDP43
(1:10,000; Proteintech) and mouse monoclonal anti-Ubiq-
uitin antibody (1:1,000; Cell Signaling) with overnight
incubation. After three washes, tissue sections were incu-
bated for 1 h in the appropriate biotinylated IgG secondary
antibodies (1:200; Vector Labs) diluted in Super Block.
Slides were washed in PBS for 15 min and immunostaining
visualized using the Vectastain Elite ABC reagent (Vector
Labs) and Vector NovaRED peroxidase substrate kit
(Vector Labs). Slides were counterstained with hematox-
ylin (Sigma Aldrich). Sections were visualized using an
Olympus BX40 light microscope and images acquired
using a Nikon DS L2 digital camera.
Semi-quantitative assessment of RBM45 and TDP-43
cytoplasmic inclusions was performed on all coded sec-
tions of the lumbar spinal cord and hippocampus by three
independent investigators. The following scoring system
was used: (-) = none; (?) = 1–3 inclusions per section;
(??) = 4–9 inclusions per section; (???) = 10 or more
inclusions per section.
Quantitative assessment of RBM45 and TDP43 pathol-
ogy was performed on select spinal cord sections. The gray
matter was morphologically identified for each lumbar
spinal cord section on pictures at 1.259 magnifications
using a Leica microscope and outlined using NIH ImageJ
software. The area of the gray matter was calculated via
the ROI (region of interest) tool of NIH ImageJ software
(1 pixel = 1.276 l). Then, counts of total motor neurons,
neuronal and glia inclusions for both RBM45 and TDP-43
were established per slide and results reported as a pro-
portion of gray matter area density for RBM45 and TDP-43
inclusions.
Confocal microscopy
For confocal microscopy, 6-lm sections were deparaffi-
nized, rehydrated, subjected to antigen retrieval, and blocked
as above. Following blocking, the slides were incubated
overnight in affinity-purified rabbit polyclonal anti-RBM45
primary antibody HPA020448 (1:75; Sigma Aldrich). For
double-label experiments, mouse monoclonal anti-TDP43
antibody (1:100; Proteintech), mouse monoclonal anti-
phosphorylated Tau AT100 antibody (1:100; Thermo Sci-
entific), or mouse monoclonal anti-Ubiquitin antibody
(1:100; Cell Signaling) was also included. Appropriate IgG
secondary antibodies were used labeled with either Alexa
488 or Alexa 594 fluorophores. Tissue sections were washed
3 times for 10 min in PBS after all antibody incubations. Cell
nuclei were stained using DAPI (1:1,000). Confocal images
were acquired using a Zeiss LSM 710 confocal microscope.
Images were analyzed and quantified for RBM45 and
TDP-43 pathology and co-localization using Zeiss Zen
software (version 2009) using 0.5-lm Z-stack sections. We
determined the percent overlap between RBM45 and TDP-
43 in at least 50 cells per subject group.
Immunoblot and tissue homogenization
CSF samples from non-neurologic disease controls (n = 9)
and ALS (n = 9) were analyzed for immunoblot. The
average age was 54.7 ± 11.9 years for the controls and
49 ± 6.4 years for the ALS patients, with no statistically
significant difference between the groups (p = 0.30). All
subjects were male. All ALS patients were limb onset with
an average time from symptom onset to lumbar tap of
782 days. Equal amounts of CSF protein (10 lg) from each
subject was mixed in SDS sample buffer and heated for
10 min at 90 C. Samples used for CSF analysis were from
living ALS patients or controls and therefore these subjects
are not included in the neuropathologic analysis.
For generation of total tissue homogenates, lumbar
spinal cord frozen tissue from controls (n = 2) and ALS
cases (n = 4) were homogenized in lysis buffer containing
25 mmol/l HEPES (pH 7.4), 50 mmol/l NaCl, protease
inhibitor cocktail II (Sigma), and 1 % Triton-X 100. The
lysates were spun at 14,000 rpm for 5 min at 4 C and the
supernatant saved as the total cell lysate. Protein concen-
trations of all samples were determined by BCA assay
(Thermo-Fisher Scientific, Waltham, MA).
All samples were fractionated by electrophoresis on
4–12 % NuPAGE Bis–Tris gels in 19 MOPS Running
Buffer at 200 V for 50 min. Proteins were transferred to
polyvinylidene difluoride nylon membranes (NEN Biolabs)
at 100 V for 1 h at 4 C and blocked in 5 % non-fat milk/
TBS-T. The blots were probed individually with a primary
antibody for RBM45 (Sigma, AV41154 that recognizes
amino acids 216-267 of RBM45) at 1:2,000 or TDP-43
(rabbit polyclonal 10782-1-AP; ProteinTech Group Inc.) at
1:1,000 dilution overnight at 4 C in 1 % milk/TBST. The
epitope recognized by AV41154 is not similar to any
sequences in TDP-43 or FUS and recognizes only one
major band by western blot. The final reaction products
were developed using SuperSignal West Pico Chemilumi-
nescent Substrate for 5 min and the band intensities were
within the linear range of detection. The integrated optical
density of bands was measured using the NIH Image J
software and statistical analysis performed by Student’s
t test using GraphPad Prism 5.0 software.
Repeat-primed PCR
100 ng of genomic DNA was used as template in a final
volume of 28 ll containing 14 ll of FastStart PCR Master
Mix (Roche Applied Science, Indianapolis, IN) and a final
concentration of 0.18 mM 7-deaza-dGTP (New England
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Biolabs, Ipswich, MA), 19 Q-Solution (Qiagen), 0.7 lM
reverse primer consisting of *4 GGGGCC repeats with an
anchor tail, 1.4 lM 6FAM-fluorescent labeled forward
primer located 280 bp telomeric to the repeat sequence,
and 1.4 lM anchor primer corresponding to the anchor tail
of the reverse primer. A touchdown PCR cycling program
was used where the annealing temperature was gradually
lowered from 70 to 56 C in 2 C increments with a 3-min
extension time for each cycle. Fragment length analysis
was performed on an AB 3730xl genetic analyzer (Applied
Biosystems, Foster City, CA) and data analyzed using
GeneScan software (version 4, ABI). The repeat-primed
PCR is designed so that the reverse primer binds at dif-
ferent points within the repeat expansion to produce
multiple amplicons of incrementally larger size, producing
a characteristic sawtooth pattern with a 6-bp periodicity.
Results
Proteomic analysis of CSF and identification of RBM45
We performed an unbiased mass spectrometry-based pro-
teomic analysis of CSF samples from ALS, healthy
controls, multiple sclerosis, Alzheimer’s disease, upper
motor neuron disease and lower motor neuron disease
patients to discover additional candidate biomarkers for
ALS. A complete and detailed description of all the pro-
teins and cellular pathways that appeared altered in ALS
versus the various controls groups will appear elsewhere.
However, from the top 400 proteins identified in the CSF,
we detected peptides from 13 nucleic acid-binding proteins
in the CSF, with many of them altered in ALS patients
(Table 4). Seven exhibited statistically significant
increased peptide counts in the CSF of all subjects when
compared across all other groups (healthy control and
disease controls). Of these, the RNA-binding protein motif
45 (RBM45) appeared in almost all ALS groups but only a
few of the control groups and was most statistically sig-
nificant and exhibited the largest effect size between ALS
and all other groups. Six other RNA-binding proteins were
detected in the CSF, two of which also had statistically
significant alterations in ALS groups versus all other sub-
ject groups (RNA-binding protein 40 and nucleolar RNA
helicase 2). Peptides to both TDP-43 and FUS were only
detected in a few of the subject groups using this mass
spectrometry-based proteomic method and therefore were
not in the top 400 proteins detected in CSF.
RBM45 is a 476 amino acid protein that exhibits
structural similarities with TDP-43 and FUS (Supplemental
Figure 1), two RNA-binding proteins contained in cyto-
plasmic inclusions of neurons and glia in ALS and FTLD
patients. RBM45 contains three RNA recognition motifs
(RRMs) whereas TDP-43 has two and FUS has one RRM.
RBM45 contains a C-terminal nuclear localization
sequence, similar to FUS, but lacks both the glycine-rich
domains contained in both TDP-43 and FUS and a defined
nuclear export sequence (Supplemental Fig. 1). RNA-
binding protein 40 (Table 4) contains two RRM domains
and will be further characterized in a future study. How-
ever, the gene is located on the Y chromosome and is
believed to participate in spermatogenesis [22], thus mak-
ing a direct link to ALS less obvious.
RBM45 protein levels in the CSF and tissue extracts
We first verified the presence of RBM45 in the CSF and
spinal cord tissue extracts of ALS and control subjects by
immunoblot. Using an affinity-purified antibody that rec-
ognizes amino acids 216–267 of RBM45 that lacks
homology to TDP-43 or FUS, RBM45 protein was evident
in all CSF samples, with a modest increase in ALS patients
(Fig. 1a). We next prepared total protein extracts from
spinal cord tissue of ALS and control subjects and detected
similar levels of RBM45 protein in all samples (Fig. 1b).
Therefore, we verified the presence of RBM45 in both CSF
and spinal cord tissue, with a trend towards increased CSF
levels in ALS patients.
Distribution of RBM45 in control and ALS spinal cord
We next examined the cell type-specific expression pat-
terns and subcellular localization of RBM45 in ALS and
control subjects using immunohistochemistry. Non-neuro-
logic disease control subjects exhibited a punctate staining
pattern for RBM45 in the nucleus and cytoplasm of motor
neurons in the lumbar spinal cord, with limited staining of
nuclei within glial cells (Fig. 2a, b). Examination of spo-
radic and non-SOD1 familial ALS spinal cord tissue
revealed RBM45-positive inclusion pathology bearing a
striking resemblance to that seen with TDP-43 or FUS in
ALS motor neurons (Fig. 2c–e). Several distinct mor-
phologies were observed, including skein-like (Fig. 2d),
globular (Fig. 2c, e), and neuritic (Fig. 2d, e) inclusions.
Prior studies have demonstrated a clearance of TDP-43
from the nucleus of neurons that harbor cytoplasmic
inclusions [23, 36]. However, we observed motor neurons
with cytoplasmic RBM45 inclusions that retained RBM45
in a speckled or diffuse staining pattern in the nucleus
(Fig. 2d). In addition, we were able to detect glial inclu-
sions that stained positive for RBM45 (Fig. 2e, f). We also
detected RBM45 inclusions in the spinal cord of familial
ALS and FTLD-TDP cases (Fig. 2g–i). A semi-quantita-
tive assessment of RBM45 and TDP-43 pathology is shown
in Table 2. Within the spinal cord, we observed nuclear




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(n = 18 of 23 cases). RBM45 glial cytoplasmic inclusions
were observed in the spinal cord from 74 % of ALS
patients (n = 17 of 23 cases). Two cases displayed RBM45
glial inclusions but no motor neuron inclusions (cases 18
and 21). Conversely, no RBM45-containing inclusions
were observed in either cell type in the spinal cord of
control subjects. From these data, there appeared to be a
relationship between the RBM45 and TDP-43 pathology
that was further examined by double-label confocal
microscopy as described below.
The anti-RBM45 antibody used above recognizes
amino acids 1–50 that contains a small region of the first
RRM and therefore potential cross-reactivity with other
proteins such as TDP-43 and FUS that contain these
domains. However, a blocking peptide to this epitope
completely eliminates immunoreactivity (Supplemental
Figure 2), suggesting that this antibody does not also
recognize similar epitopes in TDP-43 or FUS. In addition,
RBM45 amino acids 1–50 exhibit little sequence identity
to either TDP-43 or FUS. However, we also used another
commercial antibody to RBM45 that recognizes amino
acids 216–257 (lacks any RRM domain sequences) and a
custom affinity-purified rabbit monoclonal antibody to the
terminal 15 amino acids of RBM45 for immunohisto-
chemistry. Both of these antibodies could detect RBM45
inclusions in either the spinal cord or hippocampus
(Supplemental Figure 2).
Using a repeat-primed polymerase chain reaction (PCR)
method [38], we determined that three ALS patients har-
bored C9ORF72 repeat expansions, defined as having
greater than 30 repeats (Table 1). This represented 10 % of
our sporadic ALS and 33 % of our familial ALS popula-
tion. Interestingly, these subjects exhibited the highest
number of neuronal and glial cytoplasmic RBM45 inclu-
sions (Table 2). This is similar to a recent study indicating
that individuals with the C9ORF72 repeat expansion had
the highest number of p62 positive cytoplasmic inclusions
in the lumbar spinal cord and hippocampus [7]. Within the
lumbar spinal cord, ALS patients with the C9ORF72 repeat
expansion also exhibited the highest amount of TDP-43
inclusions (Table 2). We quantified the amount of RBM45
and TDP-43 inclusions within the lumbar spinal cord gray
matter for 2–4 sections of each ALS case (see ‘‘Materials
and methods’’). C9ORF72 positive cases contained on
average 12.6 RBM45 neuronal inclusions per mm2 of gray
matter whereas all other ALS cases contained 3.4 RBM45
neuronal inclusions per mm2 of gray matter. There was no
difference in the number of RBM45 inclusions within glia
in C9ORF72 repeat expansion cases.
RBM45 immunohistochemistry in the hippocampus
Since TDP-43 pathology is also evident in the dentate of
FTLD-TDP cases, we next evaluated the distribution of
Fig. 1 RBM45 immunoblot
analysis. a Representative
immunoblot comparing the
level of RBM45 between 9
control and 9 ALS CSF
samples. Equal amount of
protein (10 lg) was loaded on
each gel lane. Right panel is a
densitometric analysis for all
cases and comparison between
ALS and controls. The
difference between ALS and
controls was not statistically
significant by Mann–Whitney
t test (p = 0.28). b Immuoblot
analysis of lumbar spinal cord
tissue extracts. The band
representative of RBM45 is
similar across all samples.
Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) levels
were used as a loading control.
The right panel is a
densitometric analysis for all
cases normalized to the level of
GAPDH in each sample. No
significant difference was seen
between ALS and controls
(p = 0.89). AU Arbitrary units
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RBM45 in the hippocampus from FTLD-TDP, ALS and
control subjects. Control subjects, including both non-
neurologic controls and Alzheimer’s disease, exhibited a
punctate or speckled RBM45 pattern within the nucleus of
dentate granule cells (Fig. 3a–c). In FTLD-TDP patients
there were RBM45 positive cytoplasmic inclusions within
dentate granule cells (Fig. 3d–f). A speckled RBM45
immunoreactivity was still evident in the nucleus of dentate
granule cells in FTLD-TDP cases. RBM45 inclusions were
also detected in dentate granule neurons of ALS cases
(Fig. 3g), as well as some hippocampal pyramidal neurons
in ALS and FTLD-TDP patients (Fig. 3h, i). RBM45
dystrophic neurites were not detected in the hippocampus.
Of the available hippocampal tissue, we observed RBM45
neuronal inclusions in 63 % of ALS cases (n = 5 of 8),
with no glial inclusions in any case. While only six FTLD-
TDP cases were available for this study, RBM45 pathology
occurred in the hippocampus and/or spinal cord of all
cases. RBM45 inclusions were also observed in the dentate
gyrus and pyramidal neurons for three of four AD cases
(Table 2). We used confocal microscopy to determine
association of RBM45 with tau pathology in AD cases.
RBM45 did not co-localize with phosphorylated tau (pTau)
in the hippocampus of AD cases (Fig. 4). A speckled
RBM45 pattern was also detected within the nuclei of
dentate cells in AD cases (Fig. 4a, b). Finally, we detected
no RBM45 pathology in the hippocampus of any non-
neurologic disease control case.
Co-localization of RBM45 with TDP-43
We next examined the co-localization of RBM45 and TDP-
43 pathology in ALS, FTLD-TDP and AD by double-label
confocal microscopy, with DAPI to identify nuclei. We
detected co-localization of RBM45 and TDP-43 within
cytoplasmic inclusions of spinal cord motor neurons in
ALS (Fig. 5a–c). We also noted ALS motor neurons with
both nuclear RBM45 and co-localization in cytoplasmic
TDP-43 inclusions (Fig. 5c). Interestingly, Fig. 5a, b rep-
resents ALS cases with the C9ORF72 repeat expansion and
exhibits reduced RBM45 nuclear staining when compared
to ALS cases without the repeat expansion.
In the hippocampus of FTLD-TDP and AD patients,
RBM45 co-localized with TDP-43 in cytosolic and rare
Fig. 2 RBM45 distribution in
spinal cord by light microscopy.
Representative sections are
shown from lumbar spinal cord
sections from control, ALS and
FTLD-TDP patients stained for
RBM45 and counterstained with
hematoxylin. a, b Motor
neurons from control subjects
show a punctate staining of the
nucleus and cytoplasm.
c–e Motor neurons from ALS
patients, including a C9ORF72
case in e, contain RBM45-
positive inclusions with
globular, skein-like and neuritic
morphology. Arrow in
e indicates a glial inclusion.
f Two glial inclusions from a
sporadic ALS patient are shown
(arrows). g RBM45 positive
inclusions were also detected in
the motor neurons of non-
SOD1, non-C9ORF72 fALS
cases. h Glial inclusions are also
observed in fALS. i Spinal cord
motor neuron of FTLD-TDP
case containing skein-like
RBM45 inclusion. All images
are taken at 940 magnifications.
Scale bars equal 30 lm. Panels
represent the following case
numbers in Table 1: a 37, b 39,




Fig. 3 RBM45 localization in
the hippocampus.
Representative hippocampal
sections from ALS, FTLD-TDP
and control subjects





RBM45 is located in the nucleus
of dentate granule cells.
d–f RBM45 cytoplasmic
inclusions are observed in
dentate granule cells in FTLD-
TDP cases (arrows in e and f).
g RBM45 pathology in the
hippocampus of sporadic ALS.
h, i Rare CA3 pyramidal
neurons in FTLD-TDP cases
contained RBM45 inclusions.
For panels a and d, the
magnification is 910 and the
scale bars denote 60 lm, while
in all other panels the
magnification is 940 and scale
bars indicate 20 lm. Panels
represent the following case
numbers in Table 1: a 38, b 40,
c 39, d 29, e 27, f 26, g 17, h 29,
i 24
Fig. 4 RBM45 and tau
pathology do not overlap in AD
cases. a, b Hippocampal
sections from two AD cases
stained for RBM45 (green) and
phosphorylated tau (red) with
nuclei (DAPI-blue) in the
merged image. Abundant pTau
pathology is seen in both cases,
as well as RBM45 inclusions
marked with arrows. No overlap
of pTau pathology with RBM45
inclusions or speckled RBM45
nuclear staining is seen. Scale
bar 20 lm. Panels represent the
following case numbers in
Table 1: a 30, b 33
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intranuclear inclusions of dentate granule cells (arrows in
Fig. 5d, e). We also observed co-localization of RBM45 to
TDP-43 inclusions in the dentate of AD patients (Fig. 5f).
A speckled RBM45 nuclear staining pattern was evident in
many dentate granule cells that is distinct from the more
diffuse TDP-43 nuclear immunostaining. Using multiple
images from 10 ALS, 4 FTLD-TDP and 5 AD cases, we
determined that RBM45 was present in 64 % of the TDP-
43 inclusions in the spinal cord of ALS cases and 70 % of
the TDP-43 inclusions in the hippocampus of FTLD-TDP
and AD cases. Examples of TDP-43 inclusions that lack
RBM45 are shown in Fig. 6. We observed ALS spinal cord
motor neurons with nuclear RBM45 and weak or absent
co-localization to TDP-43 cytoplasmic inclusions (Fig. 6a).
In subjects with the C9ORF72 repeat expansion, we
also observed spinal cord motor neurons devoid of
nuclear RBM45 and lacking RBM45 positive cytoplasmic
inclusions (Fig. 6b). Finally, the hippocampus of ALS,
FTLD-TDP and AD subjects contained TDP-43 inclusions
without RBM45 (arrowheads in Fig. 6c). We did not
detect RBM45 inclusions that completely lack TDP-43
immunoreactivity.
Co-localization of RBM45 and ubiquitin
As ubiquitin-positive inclusions are a pathologic hallmark
of both ALS and FTLD-TDP [14, 26], we examined the
co-localization of RBM45 and ubiquitin-containing
inclusions in ALS and FTLD-TDP. RBM45-containing
cytoplasmic inclusions in lumbar spinal cord motor neu-
rons of sporadic and familial ALS cases were frequently
co-labeled with ubiquitin (Fig. 7a–c). RBM45 nuclear
immunoreactivity in neurons or glia lacked ubiquitin
staining (Fig. 7a, c). These results suggest that RBM45
pathology is highly coincident with ubiquitin in cytoplas-
mic inclusions, but nuclear RBM45 lacks ubiquitin.
Ubiquitin also labeled RBM45 cytoplasmic inclusions
within dentate granule cells of FTLD-TDP patients
(Fig. 7d, e). In addition, we also observed punctate RBM45
nuclear staining in cells that contained cytoplasmic ubiq-
uitin-containing inclusions (Fig. 7d, e). However, we did
not detect RBM45 within ubiquitin labeled dystrophic
neurites in the dentate of FTLD-TDP subjects (Fig. 7d),
and ubiquitin did not label the speckled nuclear RBM45
immunoreactivity (Fig. 7d, e).
Discussion
We report a new RNA-binding protein that exhibits cyto-
plasmic inclusions in spinal motor neurons and dentate
granule cells in ALS and FTLD-TDP patients. This protein,
RBM45, was identified by an unbiased mass spectrometry-
based proteomic screen of CSF and verified by immunoblot
analysis. Additional RNA- and DNA-binding proteins were
also observed in our CSF-based proteomics analyses that
Fig. 5 Double-label immunofluorescence for RBM45 (green) and
TDP-43 (red) in the spinal cord and hippocampus. a–c RBM45
co-localization with TDP-43 positive inclusions in ALS spinal cord
motor neurons. DAPI visualizes nuclei (blue) in the merged images.
RBM45 also remained in the nucleus of a motor neuron with
cytoplasmic TDP-43 inclusions (c). d–f RBM45 co-localization with
TDP-43 inclusions in the dentate gyrus of FTLD-TDP (d, e) and AD
(f) cases. Arrows denote co-localization in intranuclear (d) and
cytoplasmic (e, f) inclusions. Speckled RBM45 nuclear stain is
observed in all panels and is devoid of TDP-43. Scale bars denote
20 lm in panels a–c and 30 lm in panels d–f. Each panel represents
the following case numbers in Table 1: a 2, b 3, c 7, d 24, e 28, f 30
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warrant further investigation (Table 4). We focused efforts
in this study to RBM45 since it exhibited the most statis-
tically significant p value and highest effect size between
the ALS and control groups, was known to be develop-
mentally regulated in the nervous system, contained
structural similarities to TDP-43 and FUS, and commercial
antibodies were available. RBM45 was detected in a
punctate or speckled immunostaining pattern in the nucleus
of neurons and glia. We observed RBM45-positive inclu-
sions in motor neurons and glia in sporadic and familial
ALS cases, as well as in hippocampal neurons of FTLD-
TDP and AD patients. The most abundant RBM45 spinal
cord pathology was detected in patients that harbor the
C9ORF72 hexanucleotide repeat expansion, with almost
four times the density of motor neuron nuclear inclusions
than ALS cases without the repeat expansion (12.4 vs.
3.4 inclusions/mm2). This was not due to increased num-
bers of remaining motor neurons in the C9ORF72 cases but
an increased percentage of the remaining motor neurons
containing inclusions. There were no differences in the
amount of glial RBM45 inclusions in C9ORF72 repeat
expansion cases versus ALS cases without the repeat
expansion. We did not detect any intranuclear RBM45
inclusions in the spinal cord. Importantly, no RBM45
inclusions were detected in any region or cell type exam-
ined in control subjects. Significant co-localization of
RBM45 with TDP-43 or ubiquitin was detected within
inclusions of both ALS and FTLD-TDP patients, but
RBM45 did not co-localize with tau pathology in AD
cases. RBM45 within the nucleus was not labeled by
ubiquitin and did not co-localize with TDP-43.
Few prior studies have investigated RBM45, and our
study is the first to report on the distribution and expression
of RBM45 in the human brain and spinal cord. In control
subjects, we saw punctate staining of the nucleus and
cytoplasm of motor neurons of the lumbar spinal cord,
along with speckled nuclear staining of adjacent glia
(Fig. 2a, b). This is consistent with the initial character-
ization of the protein in rodents, which suggested that the
protein is capable of shuttling between the nucleus and
cytoplasm [43]. Moreover, we detected limited, predomi-
nantly nuclear RBM45 in a speckled staining pattern within
dentate granule cells of control subjects (Fig. 3a–c).
Nuclear speckles were commonly observed in a variety of
cell types, including neurons and glia. In mammalian cells,
they occur in interchromatin regions of the nucleus and
contain RNA [18, 40], and are dynamic structures most
commonly observed using antibodies to splicing factors
Fig. 6 TDP-43 pathology can
occur independent of RBM45
pathology in ALS and FTLD
cases. RBM45 is labeled in
green, TDP-43 denoted in red
and DAPI (blue) visualizes
nuclei in the merged images.
a Motor neuron with nuclear
RBM45 and a TDP-43 positive
inclusion that labels poorly for
RBM45. Several such
inclusions were found
throughout the lumbar spinal
cord of sALS and fALS cases.
b Motor neurons from
C9ORF72 ALS cases exhibited
nuclear depletion of RBM45.
RBM45 was not contained in
the TDP-43 inclusions in this
motor neuron. c Several TDP-43
positive, RBM45 negative
inclusions are indicated by
arrowheads in the dentate gyrus
of an FTLD case. While no
RBM45 positive inclusions
were seen, the speckled nuclear
staining pattern was observed in
several adjacent cells. Scale bar
20 lm. Panels represent the
following case numbers in
Table 1: a 7, b 2, c 27
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that function as regulators of pre-mRNA splicing [11, 29].
The speckled staining pattern seen for RBM45 is consistent
with a role as an RNA-binding protein involved in pre-
mRNA splicing.
The abundant level of RBM45 in the CSF of control
subjects suggests that this RNA-binding protein may also
have an extracellular function. Numerous RNA species are
contained within biofluids and many have been reported as
biomarker candidates for human diseases [6, 16], and while
speculative, RNA-binding proteins such as RBM45 may
modulate extracellular RNA signaling between cells.
Recent evidence indicates that cultured cells stimulated to
release microRNAs also release numerous RNA-binding
proteins that may contribute to the protection of extracel-
lular micoRNAs [45].
We established a connection between RBM45 and
neurodegenerative disease by virtue of the cytoplasmic
inclusion pathology observed in a total of 91 % of ALS,
100 % of FTLD-TDP and 75 % of AD cases. We did not
identify any clinical attributes (age, gender, site of disease
onset, disease duration) that would provide insight into
why some ALS cases fail to exhibit RBM45 pathology.
Further studies are necessary to explore the mechanisms of
RBM45 inclusion formation and to characterize RBM45 in
other neurodegenerative disorders. The pattern of RBM45
inclusion pathology strongly resembles that observed for
TDP-43. Namely, we identified numerous cytoplasmic
neuronal and glial inclusions in the lumbar spinal cord of
sporadic and non-SOD1 familial ALS patients, as well as
neuronal inclusions in the hippocampus in FTLD-TDP and
AD patients. This pattern is similar to that seen for the
related proteins TDP-43 and FUS in sporadic and non-
SOD1 familial ALS cases [9, 23]. Indeed, we saw con-
siderable overlap of RBM45 and TDP-43 pathology by
confocal microscopy in ALS, FTLD-TDP and AD patients.
However, we did not detect RBM45 in TDP-43 or ubiq-
uitin-positive dystrophic neurites in the dentate gyrus of
FTLD-TDP patients (Fig. 7). We also did not observe
RBM45 in tau pathology in the hippocampus of AD
patients (Fig. 4). Assessment of co-localization with FUS
awaits future studies.
Overall, RBM45 co-localized with 64 % of cytoplasmic
TDP-43 inclusions in ALS spinal cord and 70 % of TDP-
43 inclusions in the hippocampus of FTLD-TDP and AD
cases. By confocal microscopy we did not detect any
RBM45 inclusions that were completely devoid of TDP43
immunoreactivity, suggesting that RBM45 inclusion for-
mation is always associated with TDP-43 inclusions in
these brain and spinal cord regions. By confocal micros-
copy we also noted a punctate or speckled RBM45 nuclear
staining in neurons containing RBM45, TDP-43 or ubiq-
uitin inclusions (Figs. 5, 6, 7). Retention of FUS in the
nuclei of cells harboring cytoplasmic inclusions has been
noted in ALS cases that do not harbor mutations in FUS
[12]. TDP-43 inclusions may temporally occur earlier in
the pathobiology of ALS and RBM45 may be later
sequestered into these inclusions. Future cell culture stud-
ies are necessary to determine the temporal pattern of
TDP-43 and RBM45 deposition within inclusions and if
RBM45-containing inclusions are cytotoxic. Since many
neurons were observed that had both cytoplasmic RBM45
and speckled nuclear RBM45, the formation of RBM45
Fig. 7 Double-label immunofluorescence for RBM45 (green) and
ubiquitin (red) in the spinal cord and hippocampus. a–c RBM45
co-localization with ubiquitin in ALS spinal cord motor neurons.
DAPI visualizes nuclei (blue) in the merged images. Cytoplasmic
ubiquitin inclusions are positive for RBM45; however, nuclear RBM45
is not labeled by ubiquitin (c). d, e Co-localization of RBM45 to
ubiquitin cytoplasmic inclusions in the dentate gyrus. Arrows denote
cells that exhibit co-localization of RBM45 and ubiquitin within an
inclusion but retaining a speckled RBM45 nuclear immunostain. Note
the lack of RBM45 labeling of an ubiquitin positive dystrophic neurite
in the dentate gyrus as indicated by arrowhead (d). Scale bars denote
20 lm in panels a–d and 30 lm in panel e. Each panel represents the
following case numbers in Table 1: a 10, b 7, c 22, d 27, e 26
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inclusions does not preclude its normal distribution, and
hence function, in the nucleus. It is possible that the loss of
RBM45 from the nucleus is cytotoxic and future studies
will explore this possibility.
Aside from RBM45’s affinity for poly(C) and poly
(G) RNA [43], little is known about RBM45-mediated
regulation of gene expression, and continued studies of
RBM45 function in splicing may provide insight into dis-
ease-associated dysregulation of gene expression.
Interestingly, the most abundant RBM45 pathology
occurred in the spinal cord of subjects containing the
C9ORF72 repeat expansion. Recently, ubiquitin or p62
positive and TDP-43 negative inclusions were noted in
non-motor regions including the hippocampus and cere-
bellum of subjects with the C9ORF72 repeat expansion [1,
7, 34, 41], and it is possible that RBM45 may be contained
within these inclusions in the cerebellum. We did not have
access to cerebellar tissue in these cases to explore this
question. We also noted reduced nuclear immunostaining
for RBM45 in cases that harbor the C9ORF72 repeat
expansion, though studies using a larger number of subjects
containing the repeat expansion is necessary to confirm this
observation.
The presence of RBM45 pathology in a majority of ALS
and all FTLD-TDP cases suggests that RBM45 inclusions
occur via a pathway common to familial and non-familial
forms of neurodegeneration. Prior studies have linked
mutations or gene variations in a number of RNA pro-
cessing proteins to ALS and FTLD-TDP, including TDP-
43, FUS, senataxin, the survival motor neuron protein and
ataxin-2 (reviewed in [2]). This raises the possibility that
RBM45 mutations may also occur in familial forms of ALS
or FTLD. However, the chromosomal location of the
RBM45 gene, 2q31.2, has not been linked to ALS or FTLD
in any prior genetic linkage study. Nevertheless, our data
strengthen the link between ALS and FTLD-TDP to RNA
metabolism (reviewed in [17, 42]). It is also important to
note that TDP-43 has been shown to interact with the RNA
for FUS and RBM45 in neurons, suggesting a functional
role for TDP-43 in the expression of both FUS and RBM45
[39].
In summary, we have identified a novel RNA-binding
protein in cytoplasmic inclusions of motor neurons and glia
in sporadic and familial ALS, as well as in hippocampal
neurons in FTLD-TDP and AD. RBM45 inclusions readily
co-localize with both TDP-43 and ubiquitin, but RBM45
can be distinguished from these proteins through its
speckled nuclear immunostaining and lack of incorporation
into hippocampal dystrophic neurites. The most abundant
RBM45 pathology typically occurred in patients that har-
bor the C9ORF72 repeat expansion. Additional work is
needed to understand how this protein contributes to both
the normal RNA metabolism as well as to neurodegenerative
disorders. Nevertheless, the identification of a new RNA-
binding protein associated with these disorders holds
promise for further mechanistic insights into disease path-
ogenesis and strengthens the role of RNA metabolism in
these disorders [37, 47].
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